Gut bugs linked to liver damage in new study
NCT ID NCT07313007
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how gut bacteria produce certain chemicals that might worsen fatty liver disease (MASLD). Researchers will collect stool, blood, and urine samples from 24 people with the condition and healthy volunteers. They aim to identify which bacteria are responsible for these harmful metabolites, which could lead to new treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward new treatments for fatty liver disease by targeting gut bacteria.
- What could go wrong
- This is a small, early-stage observational study with only 24 participants, so results may not apply broadly and may not lead to treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * For patients and healthy volunteers: * Age between 18 and 80 years. * Non-diabetic participant (fasting blood glucose \< 1.26 g/L, or absence of insulin therapy or oral antidiabetic medication). * Body mass index (BMI) between 18 and 30 kg/m². * For women of childbearing potential, use of at least one recognized effective contraceptive method. * Very regular bowel movements every 24 to 48 hours. * Participant living within 100 km of the Lyon Sud Hospital Center (CHLS). * Participant willing to participate in the study and providing written informed consent. * Participant affiliated with the general French Social Security system or an equivalent scheme. * For patients: * Presence of MASLD according to the definition of the European Association for the Study of the Liver (EASL), defined by hepatic steatosis on imaging performed within the previous year (abdominal ultrasound, abdominal CT scan, magnetic resonance imaging, or controlled attenuation parameter (CAP) measured by FibroScan) and at least one cardiometabolic criterion among: dyslipidemia, arterial hypertension, overweight (BMI ≥ 25 kg/m²), impaired glucose tolerance, or type 2 diabetes. * No history of liver transplantation. * No excessive alcohol consumption (less than 20 g/day for women and less than 30 g/day for men). * Patient followed in the Endocrinology, Diabetes and Nutrition Department at Lyon Sud Hospital. Exclusion Criteria: * For patients and healthy volunteers: * Participant with active inflammatory, infectious, cardiovascular, or neoplastic disease. * Participant with a history of colectomy, small bowel resection, or cholecystectomy. * Participant who received antibiotics, prebiotics, or probiotics within the past 3 months. * Participant using laxatives (more than 2 doses per day over the past 3 months). * Participant with chronic constipation. * Pregnant, parturient, or breastfeeding women. * Participant deprived of liberty by judicial or administrative decision. * Participant receiving psychiatric care. * Participant institutionalized for reasons other than research. * Adult participant under legal protection (guardianship or trusteeship). * Participant who does not understand the French language and cannot provide informed consent. * Participant already enrolled in a study presenting a conflict of interest with the present study. * For healthy volunteers * Known liver disease * No long-term drug medication except oral contraception for women.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Masld (metabolic dysfunction-associated steatotic liver disease) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Centre Hospitalier Lyon Sud Service Endocrinologie, Diabète et nutrition
RECRUITINGPierre-Bénite, 69495, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cold exposure melt away liver fat?
- Can a liver risk score predict early death from routine checkups?
- Can a weekly shot reverse liver damage from fatty liver disease?
- A simple scan and blood test could catch silent liver scarring before It's too late
- A simple body scan may spot fatty liver disease without needles
- Could a common b vitamin tame fatty liver?